Are there any drug interactions between Depakote (valproic acid) and Invega (paliperidone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, there is a clinically significant interaction between Depakote and Invega that requires dose adjustment.

When Depakote (valproic acid/divalproex sodium) is co-administered with Invega (paliperidone), Invega levels increase by approximately 50%, necessitating dose reduction of Invega based on clinical assessment 1.

Mechanism and Clinical Impact

The interaction is pharmacokinetic in nature. Co-administration of divalproex sodium extended-release (two 500 mg tablets once daily) with a single 12 mg dose of Invega resulted in approximately 50% increases in both Cmax and AUC of paliperidone 1. This elevation in paliperidone exposure is clinically meaningful and warrants dosage adjustment.

Research confirms this interaction: a prospective study demonstrated that divalproex sodium ER increased paliperidone oral bioavailability by an estimated 51% for both Cmax and AUC 2. Importantly, the interaction is unidirectional—Invega does not affect valproate levels. Studies show that patients on stable valproate doses maintained comparable valproate plasma concentrations when Invega (3-15 mg) was added 1, and steady-state VPA concentrations remained within bioequivalence criteria when co-administered with paliperidone 2.

Management Algorithm

  1. If adding Invega to existing Depakote therapy: Start Invega at a reduced dose (consider 25-50% reduction from standard dosing) and titrate based on clinical response and tolerability 1.

  2. If adding Depakote to existing Invega therapy: Reduce Invega dose by approximately one-third to account for the 50% increase in exposure, then monitor clinically 1.

  3. Monitor for: Increased antipsychotic side effects including extrapyramidal symptoms, sedation, orthostatic hypotension, and metabolic effects (weight gain, glucose/lipid abnormalities) given the elevated paliperidone levels.

  4. Clinical assessment should guide adjustments: The FDA label explicitly states "Dosage reduction for INVEGA® should be considered when INVEGA® is co-administered with valproate after clinical assessment" 1.

Additional Considerations

Both medications have CNS depressant effects, so use caution with activities requiring alertness 1. The combination may produce additive sedation and orthostatic hypotension beyond the pharmacokinetic interaction 1.

This interaction is well-established in drug labeling 1 and supported by controlled pharmacokinetic studies 2, 3, making it a high-priority interaction requiring proactive dose management rather than simple monitoring.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.